Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
How I treat cytopenias after CAR T-cell therapy
Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European …
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …
The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following …
Abstract CD19‐directed CAR T‐cell therapy with brexucabtagene autoleucel (brexu‐cel)
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …
has substantially improved treatment outcomes for patients with relapsed/refractory mantle …
Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management
Multiple myeloma is the second-most common hematologic malignancy in adults worldwide.
Despite ongoing advancement in therapeutic modalities, it remains an incurable disease …
Despite ongoing advancement in therapeutic modalities, it remains an incurable disease …
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the
treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent …
treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent …
Recognizing, defining, and managing CAR-T hematologic toxicities
Autologous CAR-T cell therapy (CAR-T) has improved outcomes for patients with B-cell
malignancies. It is associated with the well-described canonical toxicities cytokine release …
malignancies. It is associated with the well-described canonical toxicities cytokine release …
Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: A focused review
Anti-B-cell maturation antigen therapies consisting of bispecific antibodies, antibody–drug
conjugates, and chimeric antigen receptor T cells have shown promising results in relapsed …
conjugates, and chimeric antigen receptor T cells have shown promising results in relapsed …
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and …
Impaired function of hematopoiesis after treatment with chimeric antigen T‐cells (CAR‐T) is
a frequent finding and can interest a wide range of patients, regardless of age and …
a frequent finding and can interest a wide range of patients, regardless of age and …
Prolonged haematologic toxicity in CAR‐T‐cell therapy: A review
Q Liu, T Hu, H Li, Y Shen, D Wu… - Journal of Cellular and …, 2023 - Wiley Online Library
Chimeric antigen receptor‐T‐cell (CAR‐T‐cell) therapy is a novel immunotherapy with
encouraging results for treatment of relapsed/refractory haematologic malignancies. With …
encouraging results for treatment of relapsed/refractory haematologic malignancies. With …